A prediction score for individuals at risk for Systemic Lupus Erythematosus (SLE) by integrating clinical, serologic and transcriptomic data

Concept

Systemic Lupus Erythematosus (SLE; «lupus») begins several years before the actual time of diagnosis, when a person has no or very mild symptoms but her/his immune cells start malfunctioning and produces antinuclear («ANAs») and other auto-antibodies (so called «preclinical lupus»). This gives an opportunity for planning preventive strategies which could potentially restore immune system function and delay (or even, prevent) lupus.

Facts and figures

Project lead
G Bertsias
University of Crete
gbertsias@uoc.gr
FOREUM research grant: € 400.000
2018 - 2021

Meet the team

G Bertsias
University of Crete
A Stara
Arthritis Foundation Crete
A Tincani
University of Brescia
M Mosca
University of Pisa
L Inês
Centro Hospitalar E Universitario de Coimbra
K Lerstroem
Lupus Europe
C Pamfil
University of Medicine and Pharmacy
S Jacobsen
Copenhagen University
E Dermitzakis
University Hospitals of Geneva
A Fanouriakis
University Hospital

Objectives

To integrate demographic, family history, environmental (smoking, diet, exercise, alcohol use, working environment), clinical and serological data, with genotypes and whole-blood gene profiling towards developing a “lupus risk” prediction model.

Patient voice

The Arthritis Foundation of Crete and Lu- pus Europe participate in the consortium and have been involved in the discussions and the design of the study. Their representatives will participate in all consortium meetings where the study details will be finalized and the results will be presented and discussed.

In all phases, the patients‘ views will be incorporated as much as possible. Besides helping with patient recruitment and  retention strategies (possible risk of the project), the Foundation will assist in interpretation and dissemination of the results.

Interim results

The study protocol, including the questionnaires for assessment of environmental factors and the biosampling strategy, has been approved by all participating centres and IRBs.

More than 260 individuals at-risk for SLE have already been recruited to the study (complete data and biosampling) with follow-up assessments. Incident cases of SLE have also been captured.